Sakurai Hiroaki
Department of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
Yakugaku Zasshi. 2017;137(2):141-144. doi: 10.1248/yakushi.16-00229-4.
Receptor tyrosine kinases (RTKs) are known to be key regulators of cancer cell proliferation, migration, invasion and metastatic spread. Ligand-binding to the extracellular domain triggers canonical activation of the intracellular tyrosine kinase domain. In contrast, it has become evident that RTKs are also regulated by non-canonical tyrosine kinase-independent mechanisms via phosphorylation of their serine/threonine residues. In this review, I mainly introduce our recent findings on the non-canonical regulation of epidermal growth factor receptor (EGFR), ErbB2 and erythropoietin-producing hepatocellular receptor A2 (EphA2), and discuss the roles of non-canonical activation of RTKs in cancer progression and resistance to targeted cancer agents. Further characterization of non-canonical regulation will contribute to the development of new target cancer therapies.
受体酪氨酸激酶(RTKs)是已知的癌细胞增殖、迁移、侵袭和转移扩散的关键调节因子。配体与细胞外结构域结合会触发细胞内酪氨酸激酶结构域的经典激活。相比之下,很明显RTKs也通过其丝氨酸/苏氨酸残基的磷酸化受到非经典的酪氨酸激酶非依赖性机制的调节。在这篇综述中,我主要介绍我们最近关于表皮生长因子受体(EGFR)、ErbB2和促红细胞生成素产生肝细胞受体A2(EphA2)非经典调节的发现,并讨论RTKs非经典激活在癌症进展和对靶向抗癌药物耐药性中的作用。非经典调节的进一步表征将有助于开发新的靶向癌症治疗方法。